High percentage of evanescent red cell antibodies in patients with sickle cell disease highlights need for a national antibody database

Southern Medical Journal

Volumn 109, Issue 9, 2016, Pages 588-591

  Williams, Lance A ^a   Lorenz, Robin G ^a   Tahir, Absar ^a   Pham, Huy P ^a   Marques, Marisa B ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

delayed hemolytic transfusion reaction; evanescence; Key Words alloantibody; sickle cell disease

Indexed keywords

ALLOANTIBODY; ERYTHROCYTE ANTIBODY; RHESUS ANTIBODY;

AFRICAN AMERICAN; ANTIBODY DETECTION; ANTIBODY SCREENING; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; FEMALE; HEMOLYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; SICKLE CELL ANEMIA; ADULT; ADVERSE EFFECTS; ANTIBODY PRODUCTION; BLOOD TRANSFUSION; ERYTHROCYTE; FACTUAL DATABASE; HEALTH SERVICE; IMMUNOLOGY; MIDDLE AGED; PROCEDURES; RETROSPECTIVE STUDY; UNITED STATES; YOUNG ADULT;

ADULT; ANTIBODY FORMATION; BLOOD TRANSFUSION; DATABASES, FACTUAL; ERYTHROCYTES; FEMALE; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; ISOANTIBODIES; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; UNITED STATES; YOUNG ADULT;

EID: 84985946830     PISSN: 00384348     EISSN: 15418243     Source Type: Journal    
DOI: 10.14423/SMJ.0000000000000528     Document Type: Article

References (25)

1. Vichinsky EP. Current issues with blood transfusions in sickle cell disease. Semin Hematol 2001; 38(1 suppl 1): 14-22
2. Aygun B, Padmanabhan S, Paley C, et al. Clinical significance of RBC alloantibodies and autoantibodies in sickle cell patients who received transfusions. Transfusion 2002; 42: 37-43
3. Davies SC, McWilliam AC, Hewitt PE, et al. Red cell alloimmunization in sickle cell disease. Br J Haematol 1986; 63: 241-245
4. Davenport RD. Hemolytic transfusion reactions. In: Popovsky MA, ed. Transfusion Reactions. 3rd ed. Bethesda, MD: American Association of Blood Banks 2007 2-24
5. Ness PM, Shirey RS, Weinstein MH, et al. An animal model for delayed hemolytic transfusion reactions. Transfus Med Rev 2001; 15: 305-317
6. Pineda AA, Vamvakas EC, Gorden LD, et al. Trends in the incidence of delayed hemolytic and delayed serologic transfusion reactions. Transfusion 1999; 39: 1097-1103
7. Ness PM, Shirey RS, Thoman SK, et al. The differentiation of delayed serologic and delayed hemolytic transfusion reactions: incidence, long-Term serologic findings, and clinical significance. Transfusion 1990; 30: 688-693
8. Yazdanbakhsh K, Ware RE, Noizat-Pirenne F. Red blood cell alloimmunization in sickle cell disease: pathophysiology, risk factors, and transfusion management. Blood 2012; 19: 528-537
9. Cox JV, Steane E, Cunningham G, et al. Risk of alloimmunization and delayed hemolytic transfusion reactions in patients with sickle cell disease. Arch Intern Med 1988; 148: 2485-2489
10. de Montalembert M, Dumont MD, Heilbronner C, et al. Delayed hemolytic transfusion reaction in children with sickle cell disease. Haematologica 2011; 96: 801-807
11. Talano JA, Hillery CA, Gottschall JL, et al. Delayed hemolytic transfusion reaction/hyperhemolysis syndrome in children with sickle cell disease. Pediatrics 2003; 111(6 Pt 1): e661-e665
12. Royal College of Pathologists. Annual SHOT report 2013. http://www. shotuk.org/wp-content/uploads/2013.pdf. Published July 2014. Accessed May 10, 2016
13. Rosse WF, Gallagher D, Kinney TR, et al. Transfusion and alloimmunization in sickle cell disease. The Cooperative Study of Sickle Cell Disease. Blood 1990; 76: 1431-1437
14. Schonewille H, Haak HL, van Zijl AM. RBC antibody persistence. Transfusion 2000; 40: 1127-1131
15. Tormey CA, Stack G. The persistence and evanescence of blood groups alloantibodies in men. Transfusion 2009; 49: 505-512
16. Harm SK, Yazer MH, Monis GF, et al. A centralized recipient database enhances the serologic safety of RBC transfusions for patients with sickle cell disease. Am J Clin Pathol 2014; 141: 256-261
17. Ramsey G, Smietana SJ. Long-Term follow-up testing of red cell alloantibodies. Transfusion 1994; 34: 122-124
18. Ramsey G, Larson P. Loss of red cell alloantibodies over time. Transfusion 1988; 28: 162-165
19. McKenna DH, ed. Standards for Blood Banks and Transfusion Services. 30th ed. Bethesda, MD: American Association of Blood Banks 2016
20. Miller ST, Kim HY, Weiner DL, et al. Red blood cell alloimmunization in sickle cell disease: prevalence in 2010. Transfusion 2013; 53: 704-709
21. Vichinsky EP, Luban NL, Wright E, et al. Prospective RBC phenotype matching in a stroke-prevention trial in sickle cell anemia: a multicenter transfusion trial. Transfusion 2001; 41: 1086-1092
22. Chou ST, Jackson T, Vege S, et al. High prevalence of red blood cell alloimmunization in sickle cell disease despite transfusion from Rhmatched minority donors. Blood 2013; 8; 122: 1062-1071
23. Vichinsky EP, Earles A, Johnson RA, et al. Alloimmunization in sickle cell anemia and transfusion of racially unmatched blood. N Engl J Med 1990; 7; 322: 1617-1621
24. Delaney M, Dinwiddie S, Nester TN, et al. The immunohematologic and patient safety benefits of a centralized transfusion database. Transfusion 2013; 53: 771-776
25. Schwickerath V, Kowalski M, Menitove JE. Regional registry of patient alloantibodies: first-year experience. Transfusion 2010; 50: 1465-1470